Rita M. O'Connor - 22 Feb 2022 Form 4 Insider Report for PLx Pharma Inc.

Reporting relationship: Chief Financial Officer
Issuer ticker: N/A
Reported as of: 22 Feb 2022
Net transaction value: $0
SEC form: 4
Accepted by SEC: 24 Feb 2022, 19:16:21 UTC
Prior SEC filing: 11 Aug 2021
Next SEC filing: 16 Mar 2022
Source filing: View source filing
Reporting owner signature: /s/ Rita M. O'Connor

Key filing fact

Rita M. O'Connor filed Form 4 for PLx Pharma Inc. on 24 Feb 2022.

Key facts

This page summarizes Rita M. O'Connor's Form 4 filing for PLx Pharma Inc..
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 24 Feb 2022, 19:16.

Change

Previous filing in this sequence was filed on 11 Aug 2021.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

PLXPQ transaction Derivative

Stock Option (right to buy)

Award

Transaction value: $0
Shares: +110,000
Change %
Price: $0.000000
Shares after: 110,000
Date: 22 Feb 2022
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 110,000
Exercise price: $4.99
Footnotes: F1, F2

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 2 footnotes

Footnote F1

Grant of stock options to the Reporting Person under the Issuer's 2018 Incentive Plan, as amended.

Footnote F2

These stock options vest over a three year period as follows: 1/3 on the first anniversary of the grant date, 1/3 on the second anniversary of the grant date and 1/3 on the third anniversary of the grant date.